MorphoSys AG (MOR) Stock Analysis

What MorphoSys AG does

MorphoSys AG is a commercial-stage biopharmaceutical company dedicated to the discovery, advancement, and marketing of innovative therapeutic antibodies aimed at treating cancer and autoimmune disorders. While its commercial operations are primarily situated in the United States, its development and partnership activities span globally. A key commercial offering is Tafasitamab, an antibody prescribed for various B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company's robust developmental pipeline includes Pelabresib, a small molecule undergoing Phase II trials for myelofibrosis; Felzartamab, an antibody targeting CD38, currently in Phase I/II studies for the autoimmune condition anti-PLA2R-positive membranous nephropathy; and CPI-0209, a small molecule in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. MorphoSys also participates in several partnered programs, such as Gantenerumab, an antibody for Alzheimer's disease; Otilimab for rheumatoid arthritis; Tremfya, used in psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody focused on immuno-oncology and autoimmune diseases. Strategic alliances are crucial to its business model, encompassing a regional licensing agreement with I-Mab Biopharma for felzartamab in China, Taiwan, Hong Kong, and Macau, alongside a strategic partnership with LEO Pharma. Furthermore, MorphoSys holds a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of tafasitamab. A clinical collaboration also exists with Incyte Corporation and Xencor, Inc., exploring a combination therapy of tafasitamab, plamotamab, and lenalidomide for patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma. Established in 1992, MorphoSys AG's corporate headquarters are located in Planegg, Germany.

Key metrics

ETFs linked to MOR

Broad-market and Healthcare sector ETFs an investor holding MorphoSys AG is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how MOR fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for MorphoSys AG?

MorphoSys AG trades under the ticker MOR on NASDAQ.

Which exchange is MOR listed on?

MOR is listed on NASDAQ.

What sector does MorphoSys AG operate in?

MorphoSys AG is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze MOR in a portfolio?

PortView shows MOR's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.